A year of growing and promising data demonstrating Ampligen's potential to address multiple high-value indications
The company will host a conference call and webcast today, April 2n.d. 8:30 a.m. ET
OCALA, Fla., April 2, 2024 (Globe Newswire) — AIM Immunotec Co., Ltd. (NYSE American: AIM) (“AIM” or the “Company”) today reported its full year 2023 financial results and provided an update on its business. As previously announced, we will be holding the following events. Conference calls and webcasts Today, Tuesday, April 2, 2024, at 8:30 a.m. ET (see details below).
“AIM reported positive data on many fronts in 2023 and the first quarter of 2024. We look forward to building on this momentum throughout the year as we focus on executing on our operational, clinical and regulatory initiatives. “My goal is to create shareholder value in the short and long term as positive data continues to come in,” said Thomas K. Equels, CEO of AIM. he commented.
recent highlights
-
Announced in March 2024 Announcement of positive findings From an early access program evaluating Ampligen in the treatment of pancreatic cancer in a prestigious journal. clinical cancer research
-
AMP-518 Clinical Study: Phase 2 Study Evaluating Ampligen as a Potential Treatment for People with Post-COVID-19 Fatigue
-
Strengthening intellectual property rights in November 2023 Issuance of important US patents Combination of Ampligen and anti-PD-L1 antibodies — AstraZeneca’s Imfinzi et al.® (Durvalumab) — for the treatment of cancer
-
DURIPANC clinical trial: AIM's Phase 1b/2 clinical trial combining Ampligen and Imfinzi® For the treatment of pancreatic cancer
Expected pipeline milestones
Q2 2024
2024
Summary of financial highlights for fiscal year 2023
-
AIM reported cash, cash equivalents and marketable investments of $13.1 million at December 31, 2023, compared to $34.2 million at December 31, 2022.
-
Research and development expenses for the year ended December 31, 2023 were $10.9 million and research and development expenses for the year ended December 31, 2022 were $7.0 million.
-
General and administrative expenses were $21.1 million for the year ended December 31, 2023, compared to $13.1 million for the year ended December 31, 2022.
See the full 10-K for more information.
Conference call and webcast details
As previously announced, the Company plans to hold its quarterly conference call and webcast today, April 2, 2024 at 8:30 a.m. ET, to discuss its operational and financial results.
The conference call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer, and Dr. Christopher McAleer, Scientific Director. Interested participants and investors can access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referring to AIM ImmunoTech Conference Call.of webcast will be accessible at event page of Investor sections of our website; aimimmuno.comwill be archived for 90 days after the live event.
About AIM Immunotec Co., Ltd.
AIM ImmunoTech Inc. is an immunopharmaceutical company focused on research and development of therapeutics to treat multiple types of cancer, immune disorders, and viral diseases, including coronavirus disease (COVID-19) .The company's flagship product is a first-in-class investigational drug called Ampligen.® (rintatolimod) is a dsRNA, highly selective TLR3 agonist immunomodulator that has demonstrated broad-spectrum activity in clinical trials in globally important cancers, viral diseases, and immune system disorders.
Learn more about. aimimmuno.com Please contact the company at X, linkedinand Facebook.
Notes
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “could,” and “future” , and other variations thereof and similar expressions (as well as other expressions or words or expressions that refer to future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company advises investors of the various risk factors identified in its most recent Form 10-K and any risk factors or cautionary statements contained in any subsequent Form 10-Q or Form 8-K filed with the U.S. Securities and Exchange Commission. Encourage them to consider the matter in detail. (“SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, with respect to these statements, the Company claims safe harbor protection for forward-looking statements contained in the PSLRA. We undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of this document.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
